Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Medicare Creates New Code For Theranica’s Headache Device

Executive Summary

Medicare beneficiaries suffering from migraines will soon have access to an innovate drug-free treatment at the touch of their smartphones.

You may also be interested in...

Theranica’s Smartphone-Controlled Migraine Device Earns FDA De Novo

The FDA granted a de novo clearance to Theranica’s Nerivio Migra smartphone-controlled remote electrical neuromodulation device for acute treatment of migraine headaches.

FDA Issues Guidance To Protect Children Enrolled in Clinical Trials

The US FDA has published a draft guidance outlining its current thinking on ethical considerations for clinical trials of medical products, including devices, that enroll children.

ATA Launches Coalition To Advance Telehealth Patient Advocacy

The American Telehealth Association has created a coalition with the mission of ensuring patients have a voice in the future of telehealth.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts